Zentalis Pharmaceuticals
ZNTLClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
$0.00M $0.00M $0.00M —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($27.61M) ($22.95M) ($107.30M) ($28.72M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($8.45M) ($10.78M) ($37.72M) ($9.14M)
Operating Income / (Loss)
($36.06M) ($33.73M) ($152.81M) ($37.85M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
— — — —
Other Non-Operating Income / (Expense)
— — — —
Income Tax Provision / (Benefit)
$0.00M $0.00M $0.44M $0.12M
NET INCOME / (NET LOSS)
($26.87M) ($26.69M) ($137.06M) ($35.35M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$37.6M$39.1M$36.0M$31.9M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$37.6M$39.1M$36.0M$31.9M
Accounts Receivable, Net
$0.0M$0.0M$0.0M// --
Prepaid Expenses & Other Current Assets
$8.2M$7.6M$7.3M$6.3M
Total Current Assets
$311.6M$288.3M$253.2M$218.1M
Property, Plant and Equipment, Net
$3.1M$2.9M$2.8M$2.7M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$351.7M$327.3M$289.0M$253.1M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$3.7M$7.0M$7.2M$7.4M
Accrued Expenses & Clinical Liabilities
$35.3M$30.1M$29.4M$27.9M
Total Current Liabilities
$39.0M$37.2M$36.6M$35.2M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$38.2M$37.2M$36.2M$35.1M
Total Liabilities Block
$77.2M$74.4M$72.8M$70.4M
Total Stockholders' Equity
$274.5M$252.9M$216.2M$182.7M
TOTAL LIABILITIES & EQUITY
$351.7M$327.3M$289.0M$253.1M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
7.99x 7.76x 6.93x 6.19x
R&D Expenditure Flow
$54.9M$77.8M$107.3M$28.7M
Net Income / (Loss)
($26.87M) ($26.69M) ($137.06M) ($35.35M)
Depreciation & Amortization
$0.16M $0.16M $0.74M $0.15M
Stock-Based Compensation
$12.77M $17.60M $20.72M $3.20M
Change in Accounts Receivable
— — ($5.00M) —
Change in Prepaid Assets / Expenses
($3.01M) ($3.69M) ($2.99M) ($0.97M)
Change in Payables & Clinical Accruals
($14.61M) ($16.58M) ($17.32M) ($1.45M)
Other Operating Source / (Use) Changes
($35.78M) ($65.10M) $15.66M $1.47M
Net Cash from Operating Activities
($67.34M) ($94.31M) ($125.25M) ($32.96M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
$0.00M $0.00M $0.00M ($0.03M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
$130.00M $190.00M $250.00M $60.00M
Net Cash from Investing Activities
$70.85M $99.17M $131.62M $30.01M
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — $5.39M —
Net Cash from Financing Activities
$0.19M $0.30M ($4.28M) ($1.12M)
NET CONSOLIDATED CHANGE IN CASH
$3.70M $5.17M $2.09M ($4.07M)
Clinical Trials Registry
Registry ID
Phase / Asset
Status